Your browser doesn't support javascript.
loading
Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
Kim, Hee J; Jeon, Beom S; Jenner, Peter.
Afiliação
  • Kim HJ; Konkuk University School of Medicine, Seoul, South Korea; Parkinson Disease Study Group, Seoul National University Hospital, Seoul, South Korea.
  • Jeon BS; Parkinson Disease Study Group, Seoul National University Hospital, Seoul, South Korea; Movement Disorder Center, Neuroscience Research Institute, College of Medicine, Seoul National University, Seoul, South Korea. Electronic address: brain@snu.ac.kr.
  • Jenner P; Institute of Pharmaceutical Science, King's College London, London, United Kingdom.
Int Rev Neurobiol ; 132: 295-343, 2017.
Article em En | MEDLINE | ID: mdl-28554412
ABSTRACT
Deficit of striatal dopamine was first discovered in postmortem brain of patients with Parkinson's disease in 1960. This observation was the starting point for dopamine replacement therapy, and successful introduction of high dose l-dopa therapy in the 1969 revolutionized the treatment of Parkinson's disease. Since then, constant attempts have been made to enhance the efficacy of l-dopa and reduce motor complications by providing more continuous dopamine stimulation. This chapter traces the hallmarks of medical treatments for Parkinson's disease throughout centuries including the first description of antiparkinsonian effects of anticholinergics, the birth of apomorphine in the 1900s, then discovery of l-dopa in the 1960s, and development of dopamine agonists since the 1970s.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Levodopa / Agonistas de Dopamina / Antagonistas Colinérgicos / Antiparkinsonianos Limite: Humans Idioma: En Revista: Int Rev Neurobiol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Coréia do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Levodopa / Agonistas de Dopamina / Antagonistas Colinérgicos / Antiparkinsonianos Limite: Humans Idioma: En Revista: Int Rev Neurobiol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Coréia do Sul